Ocular Therapeutix rises as new eye drug shows longer disease control

Bayer AG

13/04/2026 12:48

** Shares of Ocular Therapeutix OCUL.O rise 1.6% to $8.93 premarket

** Biotech firm says additional late-stage data show its experimental wet AMD drug axpaxli kept eye disease under control for longer than a standard treatment

** Adds that patients on axpaxli maintained vision gains for up to a year and showed slower worsening on eye scans versus Bayer’s Aflibercept

** Patients took nearly 40 weeks to show moderate disease worsening vs 16 weeks on Aflibercept; safety issues were mostly mild and resolved over time - OCUL

** Adds that it plans to seek U.S. approval based on this single late-stage study after recent FDA guidance

** Wet AMD is an age-related eye disease that causes vision loss due to abnormal blood vessel growth in the eye

** As of last close, stock down ~28% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))